Skip to main content
. 2019 Jul 17;30(9):1789–1797. doi: 10.1007/s00198-019-05081-9

Table 1.

General characteristics of patients with a recent NVF at the FLS according to the presence of prevalent vertebral fracture

Women (n = 338)
No VF (n = 264) ≥ 1 VF Gr. ≥ 1 (n = 74) P value
Age (years) 62.9 ± 7.8 67.7 ± 8.4 .000*
Height (cm) 1.6 ± 0.1 1.6 ± 0.1 .295
Weight (kg) 74.6 ± 14.3 72.7 ± 12.1 .296
BMI (kg/m2) 27.6 ± 5.0 27.1 ± 4.0 .474
FRAX major osteoporotic fractures 82 (31.1) 30 (40.5) .126
LS aBMD (g/cm2) 0.93 ± 0.14 0.91 ± 0.17 .388
FN aBMD (g/cm2) 0.70 ± 0.11 0.67 ± 0.10 .032*
TH aBMD (g/cm2) 0.85 ± 0.13 0.81 ± 0.12 .028*
Normal BMD 72 (27.3) 13 (17.6) .113
Osteopenia 135 (51.1) 38 (51.4)
Osteoporosis 57 (21.6) 23 (31.1)
Previous fracture after age 50 years 48 (18.2) 36 (48.6) .000*
Parent fractured hip 17 (6.4) 4 (5.4) .999
Current smoking 36 (13.6) 9 (12.2) .741
Glucocorticoids 12 (4.5) 3 (4.1) .999
Rheumatoid arthritis 10 (3.8) 4 (5.4) .516
Secondary osteoporosis 70 (26.5) 21 (28.4) .749
Alcohol ≥ 3 units/day 4 (1.5) 1 (1.4) .999
History or current use of anti-osteoporosis drugs 21 (8.0) 19 (26.0) .000*
Self-reported use of anti-osteoporosis medication, n (%) 18 (6.9) 18 (24.7) .000*
 Type, n (%)#
 Alendronic acid 11 (61.1) 9 (50.0) .887
 Risedronic acid 5 (27.8) 6 (33.3)
 Zoledronic acid 0 (0.0) 1 (5.6)
 Unknown 2 (11.1) 2 (11.1)
 Duration (year), mean ± SD# 4.5 ± 2.7 5.2 ± 4.1 .577
 Current, n (%)# 3 (16.7) 10 (55.6) .015*
 History, n (%)# 15 (83.3) 8 (44.4)
 Time since cessation of treatment (year), mean ± SD# 2.6 ± 2.6 1.1 ± 2.3 .109
Falls past year 79 (30.0) 21 (28.8) .834

Variables are presented as mean ± standard deviation or number (percentage). P value < 0.05 is considered significant (*)

#In patients who have ever used anti-osteoporosis medication

VF, vertebral fracture; BMI, body mass index; LS, lumbar spine; FN, femoral neck, TH, total hip; aBMD, areal bone mineral density